Exact Sciences Corp., the Madison manufacturer of the Cologuard take-home colon cancer test, met its projected 2018 full-year revenue number, reporting total revenue of $454.5 million in an earnings statement Thursday.
The company completed 934,000 Cologuard tests in fiscal 2018, 64 percent higher than in 2017.
The company (Nasdaq: EXAS) in January stated it anticipated reporting total revenue between $454 million and $455 million. The revenue total is a 71 percent increase compared with 2017, when the company reported $266 million. Net loss for 2018 was $175 million, relative to $114 million in 2017.
The company anticipates revenue of $710 million to $730 million for 2019.
“The Exact Sciences team made tremendous progress in 2018, and we look forward to helping more people get screened for colorectal cancer in 2019 through our partnership with Pfizer,” said Kevin Conroy, chairman and CEO of Exact Sciences, in a statement provided by the company. “Our team continues working hard to advance our pipeline of liquid biopsy tests to deliver additional life-changing innovations in early cancer detection.”
Read the full article here.
;
